Kiora Pharmaceuticals Stock Performance
| KPRX Stock | USD 3.44 0.18 5.52% |
The company secures a Beta (Market Risk) of 0.48, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Kiora Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Kiora Pharmaceuticals is expected to be smaller as well. At this point, Kiora Pharmaceuticals has a negative expected return of -0.0593%. Please make sure to verify Kiora Pharmaceuticals' jensen alpha, kurtosis, as well as the relationship between the Kurtosis and price action indicator , to decide if Kiora Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Kiora Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Kiora Pharmaceuticals is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return (8.94) | Five Day Return (11.89) | Year To Date Return (35.70) | Ten Year Return (99.99) | All Time Return (99.99) |
Last Split Factor 1:9 | Dividend Date 2019-08-30 | Last Split Date 2024-06-11 |
1 | Acquisition by Shapiro Aron of 3000 shares of Kiora Pharmaceuticals at 3.6 subject to Rule 16b-3 | 09/10/2024 |
2 | Acquisition by Stengone Carmine N. of 1250 shares of Kiora Pharmaceuticals at 3.68 subject to Rule 16b-3 | 09/11/2024 |
3 | Kiora Pharmaceuticals director buys shares worth 4,600 - Investing.com | 09/12/2024 |
4 | Kiora Pharmaceuticals, Inc. Short Interest Down 13.3 percent in September | 09/30/2024 |
5 | Kiora Pharmaceuticals Reports Third Quarter Results Retinal Disease Pipeline Advancing Two Phase 2 Studies | 11/08/2024 |
6 | Acquisition by Melissa Tosca of 100 shares of Kiora Pharmaceuticals at 5.25 subject to Rule 16b-3 | 11/12/2024 |
7 | We Think Kiora Pharmaceuticals Healthy Earnings Might Be Conservative | 11/15/2024 |
8 | Acquisition by Shapiro Aron of 5000 shares of Kiora Pharmaceuticals at 0.5677 subject to Rule 16b-3 | 11/20/2024 |
| Begin Period Cash Flow | 6 M |
Kiora |
Kiora Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 354.00 in Kiora Pharmaceuticals on September 3, 2024 and sell it today you would lose (28.00) from holding Kiora Pharmaceuticals or give up 7.91% of portfolio value over 90 days. Kiora Pharmaceuticals is currently does not generate positive expected returns and assumes 3.7549% risk (volatility on return distribution) over the 90 days horizon. In different words, 33% of stocks are less volatile than Kiora, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Kiora Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Kiora Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Kiora Pharmaceuticals, and traders can use it to determine the average amount a Kiora Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0158
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | KPRX |
Estimated Market Risk
| 3.75 actual daily | 33 67% of assets are more volatile |
Expected Return
| -0.06 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.02 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Kiora Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Kiora Pharmaceuticals by adding Kiora Pharmaceuticals to a well-diversified portfolio.
Kiora Pharmaceuticals Fundamentals Growth
Kiora Stock prices reflect investors' perceptions of the future prospects and financial health of Kiora Pharmaceuticals, and Kiora Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Kiora Stock performance.
| Return On Equity | 0.14 | ||||
| Return On Asset | 0.13 | ||||
| Profit Margin | 0.20 % | ||||
| Operating Margin | (121.23) % | ||||
| Current Valuation | (19.18 M) | ||||
| Shares Outstanding | 2.97 M | ||||
| Price To Book | 0.33 X | ||||
| Price To Sales | 0.67 X | ||||
| Gross Profit | (5.14 M) | ||||
| EBITDA | (12.35 M) | ||||
| Net Income | (12.51 M) | ||||
| Cash And Equivalents | 2.43 M | ||||
| Cash Per Share | 2.64 X | ||||
| Total Debt | 106.89 K | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 1.53 X | ||||
| Book Value Per Share | 7.14 X | ||||
| Cash Flow From Operations | (9.56 M) | ||||
| Earnings Per Share | 16.53 X | ||||
| Market Capitalization | 10.75 M | ||||
| Total Asset | 13.71 M | ||||
| Retained Earnings | (146.98 M) | ||||
| Working Capital | 3.1 M | ||||
About Kiora Pharmaceuticals Performance
Evaluating Kiora Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Kiora Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Kiora Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (2.55) | (2.68) | |
| Return On Capital Employed | (1.04) | (0.99) | |
| Return On Assets | (0.91) | (0.96) | |
| Return On Equity | (2.05) | (1.95) |
Things to note about Kiora Pharmaceuticals performance evaluation
Checking the ongoing alerts about Kiora Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Kiora Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Kiora Pharmaceuticals generated a negative expected return over the last 90 days | |
| Kiora Pharmaceuticals has high historical volatility and very poor performance | |
| Net Loss for the year was (12.51 M) with loss before overhead, payroll, taxes, and interest of (5.14 M). | |
| Kiora Pharmaceuticals currently holds about 2.43 M in cash with (9.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.64. | |
| Kiora Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Latest headline from MacroaxisInsider: Acquisition by Shapiro Aron of 5000 shares of Kiora Pharmaceuticals at 0.5677 subject to Rule 16b-3 |
- Analyzing Kiora Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Kiora Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Kiora Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Kiora Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Kiora Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Kiora Pharmaceuticals' stock. These opinions can provide insight into Kiora Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Kiora Stock Analysis
When running Kiora Pharmaceuticals' price analysis, check to measure Kiora Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiora Pharmaceuticals is operating at the current time. Most of Kiora Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiora Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kiora Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiora Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.